Sanofi eager to strike new diabetes drug deals

Sanofi-Aventis is engaged in ongoing discussions aimed at forging new partnerships in diabetes drug development, says the senior medical director of its diabetes unit. Ricardo Perfetti tells Bloomberg that he expects to announce a "couple" of major new collaborations in the field in coming months.

"We're very much engaged in working not only on our own ideas and our own internal pipeline but also with external potential partners," Perfetti told the business wire. At the top of Sanofi's list of partnering prospects will be any new drug that can help succeed the long-acting insulin Lantus as well as drugs that spur insulin secretion.

Sanofi has already been a busy player in the space, striking deals for Metabolex's GLP-1 therapy and in-licensing a program from CureDM Group.

- here's the story from Bloomberg

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.